Literature DB >> 2779616

Exposure of patients to human immunodeficiency virus through the transfusion of blood components that test antibody-negative.

P D Cumming1, E L Wallace, J B Schorr, R Y Dodd.   

Abstract

The risk of transmission of the human immunodeficiency virus to recipients of blood transfusions exists chiefly during the period between the time a donor is infected and the time he or she has a positive blood test for HIV antibodies. Estimating the chance that blood will be donated during this period is an effective way to define the risk of HIV infection from transfusion. Using this approach, and employing data from over 17 million American Red Cross blood donations, we estimate that during 1987 the most likely number of units of blood infected with undetected HIV that were transfused was 131 (range, 67 to 227). For a patient, the odds of contracting HIV infection were 1:153,000 per unit transfused. A patient who received the average transfusion (5.4 units) had odds of 1:28,000. The risk has been decreasing by more than 30 percent a year. We estimate that donor-recruitment practices plus careful education and screening are eliminating 49 of every 50 donors likely to be HIV-positive and that testing is 92 to 97 percent effective, for a combined effectiveness of 99.9 percent. The risk of undetected infectious units can probably be further reduced by transfusing fewer units and units from fewer donors, recruiting more women and fewer men as new donors, and encouraging more frequent donations from donors who have been tested repeatedly.

Entities:  

Mesh:

Year:  1989        PMID: 2779616     DOI: 10.1056/NEJM198910053211405

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  16 in total

1.  Risk of HIV infection from blood transfusion in Montreal.

Authors:  R S Remis; G Delage; R W Palmer
Journal:  CMAJ       Date:  1997-08-15       Impact factor: 8.262

2.  Delphi Study: HIV/AIDS and the Athletic Population.

Authors:  W R Whitehill; K E Wright
Journal:  J Athl Train       Date:  1994-06       Impact factor: 2.860

3.  Human immunodeficiency virus infection in children who received transfusions in Mexico.

Authors:  R M Ferdman; J A Church; L Mascola; J K Sato
Journal:  West J Med       Date:  1991-11

4.  The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution.

Authors:  Håkon Reikvam; Susanne Marschner; Torunn Oveland Apelseth; Ray Goodrich; Tor Hervig
Journal:  Blood Transfus       Date:  2010-07       Impact factor: 3.443

5.  Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission.

Authors:  T Zhu; N Wang; A Carr; D S Nam; R Moor-Jankowski; D A Cooper; D D Ho
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

6.  Ensuring the safety of Canada's blood supply.

Authors:  P Gill
Journal:  CMAJ       Date:  1994-10-15       Impact factor: 8.262

7.  Evaluation of a new combined antigen and antibody human immunodeficiency virus screening assay, VIDAS HIV DUO Ultra.

Authors:  Bernard Weber; Annemarie Berger; Holger Rabenau; Hans Wilhelm Doerr
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

Review 8.  Pharmacological approaches to reduce perioperative transfusion requirements in the aged.

Authors:  T Tasaki; H Ohto; R Motoki
Journal:  Drugs Aging       Date:  1995-02       Impact factor: 3.923

9.  Risk of HIV infection from transfusion with blood negative for HIV antibody in a west African city.

Authors:  D Savarit; K M De Cock; R Schutz; S Konate; E Lackritz; A Bondurand
Journal:  BMJ       Date:  1992-08-29

10.  Reduction of diagnostic window by new fourth-generation human immunodeficiency virus screening assays.

Authors:  B Weber; E H Fall; A Berger; H W Doerr
Journal:  J Clin Microbiol       Date:  1998-08       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.